View the complete presentation (12.3 MB PDF)
Transcription
View the complete presentation (12.3 MB PDF)
Alnylam Pharmaceuticals R&D Day December 12, 2014 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. There are a number of important factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements. These important factors include our ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of our drug candidates, obtain, maintain and protect intellectual property, enforce our patents and defend our patent portfolio, obtain regulatory approval for products, establish and maintain business alliances; our dependence on third parties for access to intellectual property; and the outcome of litigation, as well as those risks more fully discussed in our most recent quarterly report on Form 10-Q under the caption “Risk Factors.” If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. All forwardlooking statements speak only as of the date of this presentation and, except as required by law, we undertake no obligation to update such statements. 2 Agenda 8:00 – 9:30 a.m. Welcome Cynthia Clayton Vice President, Investor Relations and Corporate Communications Alnylam Pipeline Growth Strategy John Maraganore, Ph.D. Chief Executive Officer Collaborating to Develop Genetic Medicines David Meeker, M.D. President and CEO, Genzyme, a Sanofi company Genetic Medicine Pipeline Highlights Akshay Vaishnaw, M.D., Ph.D. Executive Vice President and Chief Medical Officer Q&A Session Moderated by Barry Greene President and Chief Operating Officer 3 Agenda 9:30 – 10:50 a.m. Cardio-Metabolic Disease Daniel Rader, M.D. Chair, Department of Genetics, Perelman School of Medicine, University of Pennsylvania Cardio-Metabolic Pipeline Rachel Meyers, Ph.D. Vice President, Research and RNAi Lead Development Q&A Session Moderated by Barry Greene Break 4 Agenda 10:50 a.m. – 12:00 p.m. Hepatic Infectious Disease Timothy Block, M.D. President, Hepatitis B Foundation of America and its Baruch S. Blumberg Institute, and Professor, Drexel University College of Medicine Hepatic Infectious Disease Pipeline Laura Sepp-Lorenzino, Ph.D. Vice President, Entrepreneur-in-Residence and Program Leader Looking Ahead Barry Greene Q&A Session Moderated by Barry Greene Adjourn 5 John Maraganore, Ph.D. Chief Executive Officer Alnylam Pipeline Growth Strategy 6 RNA Interference (RNAi) A New Class of Innovative Medicines RNAi Therapeutics Harness natural pathway » Catalytic mechanism » Mediated by small interfering RNA or “siRNA” Therapeutic gene silencing » Any gene in genome » Distinct mechanism of action vs. other drug classes » Unique opportunities for innovative medicines Clinically validated platform 7 RNAi Clinically Validated Multiple Alnylam Programs; IV and SC Delivery Human Safety and PK >3500 Doses administered » Includes >2 years duration Generally well tolerated Both IV and SC Human Clinical Activity: Patisiran and Revusiran >90% Knockdown of serum TTR, disease causing protein Initial evidence for disease stabilization » Patisiran Phase 2 OLE Both IV and SC Human Clinical Efficacy: ALN-PCS02 Up to 57% reduction of LDL-C w/out statins Up to 84% knockdown of PCSK9 ALN-PCSsc Phase 1 started Human Clinical Activity: ALN-AT3 Positive results in ongoing Phase 1 in hemophilia » Up to 57% knockdown of antithrombin Highly potent and durable effects with mcg/kg SC dose Coelho et al., N Eng J Med;369:819-29 (2013); Adams, ANA, Oct. 2014; Mauer, AHA, Nov. 2014 Fitzgerald, et al., The Lancet, EOP (2013); Sorenson, ASH Dec. 2014 8 Alnylam RNAi Therapeutics Strategy A Reproducible and Modular Path for Innovative Medicines 2. POC achieved in Phase 1 Blood-based biomarker with strong disease correlation GCCCCUGGAGGG » e.g., Serum TTR, thrombin generation, hemolytic activity, LDL-C, HBsAg levels 3. Definable path to approval and market 1. Liver-expressed target gene Involved in disease with high unmet need Validated in human genetics GalNAc-siRNA enables SC dosing with wide therapeutic index Established endpoints Focused trial size Large treatment effect Collaborative approach with physicians, regulators, patient groups, and payers 9 Alnylam 5x15 TM Focused Product Development Pipeline for Genetic Medicines RNAi therapeutics as genetic medicines In 2011: 5 Key products in clinical development through 2015 Expect to exceed 2011 guidance » 6-7 Clinical-stage products » At least 2 in Phase 3 » 5-6 Human POCs 15 Programs disclosed to date » >10 Additional programs yet to be disclosed Product characteristics Genetically defined target/disease Existing Alnylam delivery platform Phase 1 proof of concept Clear and rapid development Significant commercial opportunity 10 GalNAc-siRNA Conjugates Subcutaneous RNAi Therapeutics GalNAc3 Asialoglycoprotein Receptor (ASGPR) Highly expressed in hepatocytes High rate of uptake Recycling time ~15 minutes Conserved across species Revusiran, ALN-AT3, ALN-PCSsc, ALN-CC5… siRNA conjugated to N-acetylgalactosamine (GalNAc) ligand Efficient delivery to hepatocytes following subcutaneous administration Wide therapeutic index “Enhanced stabilization chemistry” (ESC) used with all programs after revusiran » Significantly improved potency and durability GalNAc-siRNA conjugate ASGPR (pH>5) Clathrin-coated pit protein Recycling ASGPR Clathrin-coated vesicle RISC Endosome mRNA Nucleus 11 RNAi Therapeutics Profile Emerging profile for ESC-GalNAc-siRNA conjugates Attractive pharmacologic properties » » » » Subcutaneous dose administration High potency with microgram/kg (mcg/kg) doses Low volume per injection, <1 mL Durability for monthly (qM) and possibly quarterly (qQ) dose frequency Competitive profile with RNAi mechanism » Block synthesis of disease-causing protein » Efficacy independent of target protein blood levels » Clamped knockdown with low inter-individual variability Well tolerated and wide therapeutic index Supports pipeline growth beyond rare disease opportunities 12 13 14 15 16 Alnylam Strategic Therapeutic Areas (STAr) Genetic Medicines Genetically validated liver targets for rare orphan diseases High unmet needs in focused markets SC dosing Alnylam direct commercial in NA and EU Genzyme alliance for ROW commercial » Through end-2019 Cardio-Metabolic Disease Genetically validated liver targets for dyslipidemia, NASH, type 2 diabetes, and hypertension Development path in morbid subpopulations Access to larger populations thereafter Emerging genetics qM or qQ SC dosing Partnership opportunities Hepatic Infectious Disease Liver pathogen and/or host targets Sub-acute duration of treatment (~12 mo) Multiple siRNAs possible, if needed Defined opportunities with very large markets qM or qQ SC dosing Partnership opportunities 17 Alnylam Strategic Therapeutic Areas (STAr) GCCCCUGGAGGG 18 Alnylam Development Pipeline Discovery Development Phase 1 Phase 2 Phase 3 GENETIC MEDICINES Patisiran (ALN-TTR02) TTR-Mediated Amyloidosis Revusiran (ALN-TTRsc) ALN-AT3 Hemophilia and Rare Bleeding Disorders ALN-CC5 Complement-Mediated Diseases ALN-AS1 Hepatic Porphyrias Alpha-1 Antitrypsin Deficiency ALN-AAT Beta-Thalassemia/Iron-Overload Disorders ALN-TMP Primary Hyperoxaluria Type 1 ALN-GO1 Additional Genetic Medicine Programs CARDIO-METABOLIC DISEASES ALN-PCSsc Hypercholesterolemia Mixed Hyperlipidemia/Hypertriglyceridemia ALN-ANG Hypertriglyceridemia ALN-AC3 Hypertension/Preeclampsia ALN-AGT Additional Cardio-Metabolic Programs HEPATIC INFECTIOUS DISEASES Hepatitis B Virus Infection ALN-HBV Hepatitis D Virus Infection ALN-HDV Chronic Liver Infection ALN-PDL Additional Hepatic Infectious Disease Programs David Meeker, M.D. President and Chief Executive Officer Genzyme, a Sanofi Company 20 Dione (with her mother) Pompe disease Brazil www.genzyme.com | Milestones in Genzyme History 2003 Therapies approved for Fabry disease and MPS-I disease 2004 New global headquarters opens in Cambridge, MA 2006 Therapy approved for Pompe disease 1981 Genzyme founded 1983 Henri Termeer joins Genzyme 2008 Science Center opens in Framingham, MA 1986 Genzyme IPO 1980 1990 2000 1991 Genzyme’s first product approved for type 1 Gaucher disease 2010 2011 Genzyme becomes a Sanofi company 2011 David Meeker appointed CEO 1994 Second-generation enzyme replacement therapy approved for type 1 Gaucher disease 1996 Manufacturing plant opens in Allston, MA 2012 Manufacturing plant opens in Framingham, MA 2012 Oral therapy approved for MS 2013 Therapy approved for HoFH 1998 Therapy approved to facilitate thyroid cancer treatment and testing 2013 Two therapies approved in the EU for relapsing remitting MS Our Global Commitment Headquartered in the U.S. with global locations in more than 40 countries Expanding manufacturing capabilities in the U.S. and E.U. Collaborating with patient communities, physicians, universities, hospitals, charitable organizations, companies globally Serving patients in more than 100 countries Rare Diseases & Multiple Sclerosis Mikhail Gaucher disease Shani MS Joan Thyroid Cancer Tiger MS Genetic Disease Gaucher disease type 1 (2 treatments), Fabry disease, Pompe disease, MPS I disease Endocrinology Facilitating thyroid cancer treatment and testing Once-daily oral therapy for relapsing remitting MS Infusion therapy for relapsing remitting MS – 2 annual treatment courses Cardiovascular Homozygous Familial Hypercholesterolemia (HoFH) LATE STAGE PIPELINE Patisiran (with Alnylam) familial amyloid polyneuropathy Phase 3 Revusiran (with Alnylam) familial amyloidotic cardiomyopathy Phase 3 Acid sphingomyelinase Niemann Pick disease type B Phase 2 About Sanofi • • Global healthcare leader • Major biopharmacy player: 45% of revenues generated by biologics, 80% of projects in development are biologics • • • 112 industrial sites in 41 countries Diversified offering of medicines, consumer healthcare products, vaccines, generics, and animal health More than 110,000 employees in 100 countries 2013 sales: ~ €33 billion A Lifetime Commitment “My mom was just tremendous and an amazing role model for me. I know the doctors told her that I was going to die but her perseverance, dedication and ability to work closely with Genzyme and search around the world to develop a treatment was amazing.” – Brian Berman, Type 1 Gaucher disease 1983 Brian Gaucher disease type 1 1991 2001 2011 Understanding of unmet needs of patients 61% of Gaucher patients would like their treatment to be an oral formulation(1) (1) PeopleMetrics survey in Gaucher patients (n= 238) What improvements would you like to see in treatments for Gaucher Disease? Taking Care of People Ayama (with his mother) Pompe disease Sol Pompe disease Critical Elements VALUE PARTNERSHIP COMMITMENT Myths • Developing drugs for Rare Diseases is easy (easier?) • Orphan Designation allows you to price higher • Orphan disease pricing is not sustainable • Commercializing an orphan disease product is easy Transformational expanded collaboration on Rare Genetic Diseases Akshay Vaishnaw, M.D., Ph.D. Executive Vice President and Chief Medical Officer Genetic Medicine Pipeline Highlights 32 33 Alnylam Development Pipeline Discovery Development Phase 1 Phase 2 Phase 3 GENETIC MEDICINES Patisiran (ALN-TTR02) TTR-Mediated Amyloidosis Revusiran (ALN-TTRsc) ALN-AT3 Hemophilia and Rare Bleeding Disorders ALN-CC5 Complement-Mediated Diseases ALN-AS1 Hepatic Porphyrias Alpha-1 Antitrypsin Deficiency ALN-AAT Beta-Thalassemia/Iron-Overload Disorders ALN-TMP Primary Hyperoxaluria Type 1 ALN-GO1 Additional Genetic Medicine Programs CARDIO-METABOLIC DISEASES ALN-PCSsc Hypercholesterolemia Mixed Hyperlipidemia/Hypertriglyceridemia ALN-ANG Hypertriglyceridemia ALN-AC3 Hypertension/Preeclampsia ALN-AGT Additional Cardio-Metabolic Programs HEPATIC INFECTIOUS DISEASES Hepatitis B Virus Infection ALN-HBV Hepatitis D Virus Infection ALN-HDV Chronic Liver Infection ALN-PDL Additional Hepatic Infectious Disease Programs Alnylam Development Pipeline Discovery Development Phase 1 Phase 2 Phase 3 GENETIC MEDICINES Patisiran (ALN-TTR02) TTR-Mediated Amyloidosis Revusiran (ALN-TTRsc) ALN-AT3 Hemophilia and Rare Bleeding Disorders ALN-CC5 Complement-Mediated Diseases ALN-AS1 Hepatic Porphyrias Alpha-1 Antitrypsin Deficiency ALN-AAT Beta-Thalassemia/Iron-Overload Disorders ALN-TMP Primary Hyperoxaluria Type 1 ALN-GO1 Additional Genetic Medicine Programs ALN-PCSsc ALN-ANG ALN-AC3 ALN-AGT ALN-HBV ALN-HDV ALN-PDL Transthyretin-Mediated Amyloidosis (ATTR) Program Unmet Need and Product Opportunity RNAi to treat genetic disease ATTR is significant orphan disease » Clinical pathology » » ~50,000 Patients worldwide Onset ~40 to >60 yr; fatal within 5-15 years Two predominant forms – Familial amyloidotic polyneuropathy (FAP) – Familial amyloidotic cardiomyopathy (FAC) Halting disease progression remains unmet need » » Liver transplantation required early TTR stabilizers provide modest benefit Mutant transthyretin (TTR) is genetic cause Autosomal dominant with >100 defined mutations Misfolds and forms amyloid deposits in nerves, heart, other tissues RNAi opportunity as potentially transformative therapy Aim to halt progression, possibly achieve regression Value proposition supported by pharmacoeconomics and cost of disease burden Concentrated provider base and active patient community 36 Patisiran (ALN-TTR02) Familial Amyloidotic Polyneuropathy (FAP) Patisiran in clinical development International Nonproprietary Name designation for ALN-TTR02 = Patisiran (pa-TEE-sa-ran) Orphan drug status in US/EU Fast track designation by FDA Administered by IV infusion Positive Phase 1 results in human volunteers » Data published in New England Journal of Medicine Positive multi-dose Phase 2 results in FAP patients Phase 2 Open-Label Extension (OLE) study ongoing » Includes clinical endpoints measured every 6 months » Positive initial data reported at ANA, October 2014 » 12 month OLE readout in 2015 Phase 3 trial ongoing » Currently 31 sites in 11 countries » Expect APOLLO to enable NDA submission ~2017 37 Patisiran Open-Label Extension (OLE) Study FAP patients dosed in Phase 2 trial eligible for Phase 2 OLE study Clinical endpoints evaluated every 6 months for up to 2 years » Clinical endpoints same as APOLLO Phase 3 study » Dosing at 0.30 mg/kg IV every 3 weeks Study objectives » Primary: Safety and tolerability of long-term dosing with patisiran » Secondary: Effects on neurologic impairment (mNIS+7), quality of life, mBMI, disability, mobility, nerve fiber density in skin biopsies, and serum TTR levels Status Ongoing; enrollment completed (N=27) 6 mo mNIS+7 patient data (N=19) and serum TTR lowering » Presented at ANA, October 12-14, 2014 Report data at least once annually 38 Patisiran Phase 2 OLE Preliminary Study Results Change in mNIS+7 at 6 Months (N=19) Neuropathy Impairment Score (mNIS+7) stable after 6 months treatment with patisiran Mean decrease of 0.95 points observed Compares favorably with an up to 10 point increase estimated from historical data sets Similar result in patients with/without concurrent TTR stabilizer therapy Well tolerated out to 1 year dosing » No drug-related SAEs, no significant lab findings, low incidence of mild infusion-related reactions (~15%) 125 Change from Baseline to Month 6 Each line represents individual patient mNIS+7 Mean Δ Median Δ SEM Total -0.95 0.00 2.59 NIS-weakness 0.08 0.00 1.53 NIS-reflexes -0.39 0.00 0.43 QST -0.68 -2.00 1.82 NCS Σ5 0.11 0.00 0.15 Postural BP -0.05 0.00 0.10 mNIS+7 (points) 100 75 50 25 0 0 1 2 3 4 5 6 Months on treatment Historical Data Sets Mean (SEM) D mNIS+7 at 6 mos. Natural History Tafamidis Fx1A-201 Diflunisal Phase 3 8.9 ± 5.7 (linear) 10.3 ± 5.7 (non-linear) PBO: 8.7 ± 2.0 Drug: 2.5 ± 2.9 PBO: 7.4 ± 6.9 Drug: 2.3 ± 6.0 Adams, ANA Oct. 2014 39 Phase 3 Trial of Patisiran in FAP Study Ongoing Randomized, double-blind, placebo-controlled, global study Sample size and randomization » » N=200 2:1, Patisiran vs. placebo Key eligibility criteria » » V30M and non-V30M FAP Baseline FAP stages 1 and 2 Treatment regimen » » Patisiran 0.30 mg/kg vs. placebo IV q3w for 18 months All completers eligible for patisiran treatment on Phase 3 OLE study Primary Endpoint mNIS+71 at 18 months Secondary Endpoints Norfolk QOL-DN, NIS-weakness, mBMI, timed 10-meter walk, COMPASS-31 autonomic symptom score Statistical Considerations Placebo mNIS+7 progression rate of 17.8 points/yr derived from natural history study of 283 FAP patients Study with 90% power to detect as little as 37.5% difference in ΔmNIS+7 between treatment groups with 2-sided alpha=0.05 Blinded interim analysis 1Suanprasert et al., J Neurol Sci., 344(1-2):121-8 (2014) 40 Revusiran (ALN-TTRsc) Familial Amyloidotic Cardiomyopathy (FAC) Revusiran in clinical development International Nonproprietary Name designation for ALN-TTRsc = Revusiran (re-VOO-si-ran) Subcutaneous delivery Completed GLP tox studies confirming wide therapeutic index Positive Phase 1 study results » Normal healthy volunteer study in UK Positive initial pilot Phase 2 study results » TTR cardiac amyloidosis patients Phase 2 Open-Label Extension (OLE) study initiated November 2014 » Includes clinical endpoints measured every 6 months study ongoing » Screening study examining prevalence of TTR mutations in patients suspected of having cardiac amyloidosis » Multi-center study; up to 1,000 patients Phase 3 trial initiated 41 GalNAc-siRNA Conjugates Subcutaneous RNAi Therapeutics GalNAc3 Asialoglycoprotein Receptor (ASGPR) Highly expressed in hepatocytes High rate of uptake Recycling time ~15 minutes Conserved across species Revusiran, ALN-AT3, ALN-PCSsc, ALN-CC5… siRNA conjugated to N-acetylgalactosamine (GalNAc) ligand Efficient delivery to hepatocytes following subcutaneous administration Wide therapeutic index “Enhanced stabilization chemistry” (ESC) used with all programs after revusiran » Significantly improved potency and durability GalNAc-siRNA conjugate ASGPR (pH>5) Clathrin-coated pit protein Recycling ASGPR Clathrin-coated vesicle RISC Endosome mRNA Nucleus 42 GalNAc-siRNA Conjugates Wide Therapeutic Index from Non-Clinical GLP Studies NOAEL1 4 or 7 weeks (mg/kg) NOAEL 13 weeks (mg/kg) Rat NHP Rat NHP Revusiran3 30 ≥300 N/A ALN-AT33,4 1 0.3 ALN-PCSsc ≥250 ALN-CC5 ALN-AS1 NOAEL 6 mos Rat (mg/kg) NOAEL 9 mos NHP (mg/kg) Expected Human Therapeutic Index (TI)2 N/A 30 ≥200 >80 N/A N/A Ongoing Ongoing >10 ≥250 Ongoing Ongoing Planned Planned >500 ≥50 ≥100 Ongoing Ongoing Planned Planned >200 N/A N/A ≥30 ≥150 Planned Planned >500 1No Adverse Event Level (NOAEL) calculated as NOAEL in NHP/Expected dose in man 37 week studies 4NOAEL in hemophilia mice >100 mg/kg, qW x 7 2TI 43 Revusiran Phase 1 Study Results Randomized, double-blind, placebo-controlled SAD and MAD study in healthy volunteers Rapid, dose-dependent, consistent, and durable knockdown of serum TTR with SC dosing » Significant knockdown of serum TTR (p<0.01) up to 94% TTR knockdown; Mean knockdown up to 92.4% Excellent correlation of human to non-human primate TTR knockdown on mg/kg basis » Confirmation of human translation of GalNAc-siRNA conjugate platform » Extended durability in human vs. NHP due to attenuated nuclease environment -20 0 20 40 60 Revusiran dose groups 80 Placebo (n=3) 2.5 (n=3) 5.0 (n=3) 10.0 (n=3) Relative to Baseline % Mean TTR Knockdown Relative to Baseline (± SEM) % Mean TTR Knockdown 0 20 40 60 Human NHP 80 100 100 0 Revusiran (mg/kg), qd x5; qw x5 Days 10 Revusiran Single 10.0 mg/kg Injection Zimmermann, HFSA, Sep. 2013; Manoharan, TIDES, May 2014 44 20 30 Days 40 50 60 Preliminary Revusiran Phase 2 Study Results* Open label, multi-dose study in patients with TTR cardiac amyloidosis, FAC and SSA N=26; 14 FAC/12 SSA Up to 98.2% TTR knockdown with similar effects toward WT and mutant protein Treatment Mean (SEM) % Serum TTR Knockdown ( Rel. to Baseline) 0 N=22 N Individual Max KD (%) Mean ± SD Max KD (%) All 22 98.2 87.2 ± 9.1 5.0 mg/kg 19 97.7 86.4 ± 9.4 7.5 mg/kg 3 98.2 92.1 ± 5.4 1.0 0.9 N=19 20 0.8 N=3 0.7 40 0.6 60 0.4 N=15 0.3 80 0.2 N=18 Revusiran Dose Group 5.0 mg/kg 7.5 mg/kg 100 0.1 0.0 0 10 20 30 Revusiran (mg/kg), qd x5; qw x5 40 50 60 70 80 90 100 Days since first visit * Results as of October 3, 2014; Maurer, AHA, November 2014 45 Revusiran Phase 1 and 2 Studies Clinical Safety Summary Total of 92 dosed with ALN-TTRsc Phase 1 = 66 healthy adult volunteers Phase 2 = 26 patients with TTR cardiac amyloidosis Generally well tolerated Phase 1: 4 non drug-related discontinuations Phase 2: no discontinuations Across both studies ~25% ISRs, typically mild and associated with transient erythema One possibly related drug-related serious adverse event, per below Laboratory-related AEs Phase 1 » 1/66 (1.5%) with transient LFT changes (3-4 fold increase in ALT and <2 fold increase in AST) graded mild in subject with abnormal LFTs at baseline Phase 2 » 4/26 (15%) with LFT changes – – Transient, mild (<1.5 x ULN ALT) in 3 of 4 patients with no interruption in dosing 1 possibly related SAE for LFT changes (~4 x ULN ALT/AST), which resolved during continued dosing; graded mild in severity » 4/26 (15%) with transient, mild, and clinically insignificant increases in percent monocytes, which all occurred in patients with elevated percent monocyte counts at baseline Phase 1 data as of Nov. 18, 2014; Phase 2 data as of Oct. 3, 2014; Both Phase 1 and Phase 2 data are from unlocked databases and results subject to change 46 Revusiran Open-Label Extension (OLE) Study Patients dosed in Phase 2 trial eligible for Phase 2 OLE study Dosing for up to 2 years » Fixed subcutaneous dose of 500 mg; QDx5 followed by QW Study objectives » Primary: Safety and tolerability of long-term dosing with revusiran » Secondary: Effects on mortality, hospitalization, and serum TTR levels » Additional exploratory clinical endpoints evaluated every 6 months: Cardiac imaging (echo and MRI), amyloid burden by technetium scans and fat pad aspirates, cardiac biomarkers (BNP, troponins), 6MWD, NYHC, and QOL Status Study initiated November 2014 Expect to report data at least once annually, starting in 2015 47 Phase 3 Trial of Revusiran in FAC Randomized, double-blind, placebo-controlled, global study Study Initiated Sample size and randomization » » N=200 2:1, revusiran vs. placebo Key eligibility criteria » » » » Documented TTR mutation, including V122I or other Amyloid deposits on biopsy (cardiac or non-cardiac) History of heart failure Evidence of cardiac involvement by echo Treatment regimen » » Revusiran 500mg q daily x5, then q weekly for 18 mos All completers eligible for revusiran treatment on Phase 3 OLE study Co-Primary Endpoints Change in 6-MWD at 18 months compared to baseline Percent reduction in serum TTR burden over 18 months Composite CV mortality and CV hospitalization, change NYHA class, change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Secondary Endpoints Statistical Considerations Design informed by natural history study of TTR cardiac amyloidosis patients, including decrease in 6-MWD over time » Results expected to be presented in early ’15 Study with 90% power to detect as little as 39% difference in 18 mo change from baseline 6-MWD between treatment groups with significance level of p < 0.05 Unblinded interim analysis for futility may be conducted when ~50% of patients reach 18 mos 48 Hemophilia and Rare Bleeding Disorders Program Unmet Need and Product Opportunity RNAi to treat hemophilia and rare bleeding disorders (RBD) Hemophilias are recessive X-linked monogenic bleeding disorders » Hemophilia A: loss of function in Factor VIII – >40,000 Patients in EU/US » Hemophilia B: loss of function in Factor IX – ~9,500 Patients in EU/US Segments of high unmet need remain » E.g., “Inhibitor” patients1,2 – 2,000 Patients in major markets; up to 6,000 WW – >15-25 Bleeds/year; >5 in-hospital days/year – ~$300,000/year avg. cost; up to $1M/year Hemophilia A and B represent >$9B market » » » » Premium pricing established Value supported by pharmacoeconomics Well organized patient advocacy Significant opportunity for global expansion 1 WFH 2012 Global Survey; 2 Antunes et al., Haemophilia. 20:65-72 (2014) 49 Antithrombin and ALN-AT3 Program Intrinsic system Antithrombin (AT) is genetically defined target AT is key natural anticoagulant Extrinsic system Hemophilia B FIX FVIIa FX FIXa FVII Hemophilia A » Inactivates factors Xa and thrombin » Attenuates thrombin generation FVIII FVIIIa AT AT FXa Human AT deficiency associated with increased thrombin generation Expressed in liver; circulates in plasma FVa Prothrombin Co-inheritance of thrombophilic traits in hemophilia FV Thrombin Fibrinogen Fibrin Associated with milder bleeding, reduced factor Blood clot requirements, fewer complications Includes heterozygous ALN-AT3 in clinical development » Antithrombin deficiency ESC-GalNAc-siRNA for SC dosing » Factor VLeiden Positive initial Phase 1 results » Protein C deficiency Orphan drug status in U.S./EU (HA/HB) » Protein S deficiency Phase 1 MAD study in patients ongoing Kurnik et al., Haematologica; 92:982-5 (2007); Ettingshausen et al., Thromb Haemost; 85:218-20 50 (2001); Negrier et al., Blood; 81:690-5 (1993); Shetty et al., Br J Haematol; 138:541-4 (2007) Genetic Validation for ALN-AT3 Co-Inheritance of Type 3 VWD and AT Deficiency Human genetic data support targeting AT for treatment of hemophilia and rare bleeding disorders Type 3 von Willebrand disease (VWD) is severe genetic bleeding disorder Recently reported study of two Type 3 VWD sibs » Sib 1: very mild clinical phenotype found to have co-inherited heterozygous AT deficiency » Sib 2: severe bleeding phenotype requiring routine von Willebrand factor prophylaxis Sib 1 Sib 2 Type 3 VWD Mild Bleeding Severe Bleeding AT Levels at 57% Normal Fischer, WFH, May 2014 51 ALN-AT3 Pre-Clinical Efficacy Potent AT Knockdown and Normalization of Thrombin Generation Potent AT knockdown and normalized thrombin generation in non-human primates (NHP) Weekly SC doses for >5 months result in potent, dose-dependent, and durable AT knockdown In NHP hemophilia “inhibitor” model, ALN-AT3 normalizes thrombin generation 1.6 40 60 80 100 -20 1.2 1.0 (Peak Thrombin) Relative Thrombin Generation† p<0.01 20 (Pre-dose = 1) % Mean AT Knockdown 0 0.8 0.6 0.4 0.2 0.0 0 20 40 60 80 100 120 140 160 Pre-dose Saline Normal Recovery Recovery 1.5 mg/kg qw x 5 Recovery 0.25 0.5 Hemophilia A 0.125 mg/kg qw x 12 (Induced) †similar 1 mg/kg q2w x 4 ~80% AT KD ALN-AT3 (mg/kg) qw Day 0.5 mg/kg qw x 8 ~60% AT KD results obtained by ETP (p<0.01 at 0.50 mg/kg) 0.25 mg/kg qw x 12 Akinc, ISTH, July 2013 52 ALN-AT3 Pre-Clinical Efficacy Potent AT Knockdown and Normalization of Thrombin Generation Potent AT knockdown and normalized thrombin generation in non-human primates (NHP) Weekly SC doses for >5 months result in potent, dose-dependent, and durable AT knockdown In NHP hemophilia “inhibitor” model, ALN-AT3 normalizes thrombin generation 1.6 40 60 80 100 -20 1.2 1.0 (Peak Thrombin) Relative Thrombin Generation† p<0.01 20 (Pre-dose = 1) % Mean AT Knockdown 0 0.8 0.6 0.4 0.2 0.0 0 20 40 60 80 100 120 140 160 Pre-dose Saline Normal Recovery Recovery 1.5 mg/kg qw x 5 Recovery 0.25 0.5 Hemophilia A 0.125 mg/kg qw x 12 (Induced) †similar 1 mg/kg q2w x 4 ~80% AT KD ALN-AT3 (mg/kg) qw Day 0.5 mg/kg qw x 8 ~60% AT KD results obtained by ETP (p<0.01 at 0.50 mg/kg) 0.25 mg/kg qw x 12 Akinc, ISTH, July 2013 53 ALN-AT3 Survival Benefit in Hemophilia A Mice Results from GLP Chronic Toxicology Study ALN-AT3 shows disease modifying effects in hemophilia A (HA) mice Ongoing 26 week GLP toxicology study » 3 Study groups (N=70/group): saline, 10 mg/kg ALN-AT3, and 30 mg/kg ALN-AT3; SC, qW x 26 » » No adverse clinical signs, changes in body weight, hematology or lab chemistry in ALN-AT3 animals Survival benefit noted in treated animals (p <0.0001; Log-rank, Mantel-Cox test) Interim results through week 25 Survival of HA Mice % Survival 100 50 Treatment Groups Saline 10 mg/kg ALN-AT3 30 mg/kg ALN-AT3 0 0 50 100 150 200 Days Akinc ASH, Dec. 2014 54 ALN-AT3 Phase 1 Study Dose-Escalation Study in Two Parts Primary objectives Safety, tolerability Secondary objectives AT knockdown, thrombin generation Part A SingleAscending Dose (SAD) 30 mcg/kg x 1 SC Randomized 3:1, N=4 Single-blind Placebo-controlled Healthy volunteers f 15 mcg/kg qW x 3 SC Part B MultipleAscending Dose (MAD) G 45 mcg/kg qW x 3 SC Open-label Hemophilia A or B N=3/cohort Ongoing TBD mcg/kg qW x 3 SC 55 Up to 4 additional cohorts ALN-AT3 Phase 1 Study Part A (SAD)* Pharmacodynamics and Clinical Activity AT knockdown after single dose in human volunteers Maximum AT knockdown relative to baseline up to 28% Mean maximum AT knockdown of 19% ± 4.4% (mean ± SEM) » Placebo vs. treated, ANOVA p < 0.01 AT knockdown durable for over 60 days -20 Treatment Group Mean % AT Knockdown ALN-AT3 30 mcg/kg Placebo -10 0 10 20 30 40 0 10 20 30 40 50 60 70 80 Days *Cohort 1 data as of Nov. 24, 2014; cohort 2 data as of Dec. 5, 2014 Sorensen ASH, Dec. 2014 56 ALN-AT3 Phase 1 Study Part A (SAD)* Pharmacodynamics and Clinical Activity Increase in thrombin generation with AT knockdown Significant association between AT knockdown and peak thrombin generation Up to 152% increase in peak thrombin generation Mean maximum increase of peak thrombin 138% ± 8.9% (mean ± SEM) %Increase Peak Thrombin Generation » Consistent with increased sensitivity for thrombin generation increase with AT knockdown in background of normal levels of Factor VIII or IX 200 (r= 0.44, p=0.004) 150 100 50 0 -50 -100 -20 -10 0 10 20 30 40 % AT Knockdown *Cohort 1 data as of Nov. 24, 2014; cohort 2 data as of Dec. 5, 2014 Sorensen ASH, Dec. 2014 57 ALN-AT3 Phase 1 Study Part B (MAD)* Cohort 1 and 2 Interim Pharmacodynamics and Clinical Activity Initial data on AT knockdown after multi-dose in hemophilia subjects Cohort 1 (n=3) results » » » Mean maximum AT knockdown of 27% ± 13% (mean ± SEM) Maximum AT knockdown up to 52% in most advanced subject; nadir at day 35 Conclusions from thrombin generation measurements are pending further analysis » » AT knockdown in first subject up to 57%; data from local lab reporting Thrombin generation results pending cohort completion Cohort 2 (n=1) results ALN-AT3 Treatment Group -20 % AT Mean Knockdown 15mcg/kg 45mcg/kg 0 20 40 60 80 0 5 10 15 20 25 30 Days *Cohort 1 data as of Nov. 24, 2014; cohort 2 data as of Dec. 5, 2014 Sorensen ASH, Dec. 2014 58 ALN-AT3 Phase 1 Study* Safety/Tolerability; All TEAEs Part A (SAD), Healthy Adult Volunteers Cohort 1 N=4 1 Relationship to Study Drug Unlikely related Coryza 1 Not related Headache 1 Possibly related Panic like symptoms 1 Unlikely related Upper Respiratory Tract Infection 1 Not related Adverse event Atypical chest pain Part B (MAD), Hemophilia Subjects Adverse event Muscle Bleed Venipuncture bleed Idiopathic abdominal pain Joint Bleed Myalgia Nose Bleed Oral mucosal bleed Cohort 1 N=3 2 2 1 1 1 1 0 Cohort 2 N=1 0 0 0 0 0 0 1 Relationship to Study Drug Not related Not related Not related Not related Possibly related Not related Not related No serious adverse events All adverse events mild/moderate and no discontinuations No injection site reactions No thromboembolic events or clinically significant D-dimer increases Normal physical exams, vital signs, and ECG No laboratory AEs (LFTs, CBC, coagulation parameters) *Cohort 1 data as of Nov. 24, 2014; cohort 2 data as of Dec. 5, 2014 Sorensen ASH, Dec. 2014 59 Clinical Development Plan ALN-AT3 for the Treatment of Hemophilia and RBD Broad-based development plan to maximize product opportunity Phase 1 Adult Healthy Volunteers and Hemophilia A/B Key Objectives • Safety, PK, clinical activity (AT knockdown, thrombin generation) • Initial dose finding Phase 2 Hemophilia A/B ± Inhibitor Key Objectives • Safety, PK, clinical activity (AT knockdown, thrombin generation, bleeding frequency) • Extended dosing (3-6 mo) Phase 3 Inhibitor On-demand (Non-Inhibitor) Prophylaxis (Non-Inhibitor) RBDs Pediatric (< 12 y.o.) ± Inhibitor 60 Complement Disease Program Unmet Need and Program Opportunity Complement-Mediated Diseases Excessive complement activity drives disease pathophysiology in many indications » » » » » Paroxysmal nocturnal hemoglobinuria (PNH) Atypical hemolytic uremic syndrome (aHUS) Neuromyelitis optica (NMO) Myasthenia gravis Many others SolirisTM (eculizumab) is blockbuster drug » >$1.5B in reported 2013 sales » >$2.0B in forecasted 2014 revenue New therapeutic options needed Consistent level of efficacy SC delivery for more tolerable treatment regimen Reduce access barriers to treatment 61 Complement C5 and ALN-CC5 Program Complement C5 is genetically validated target Key component of terminal pathway » C5 cleavage releases C5a; initiates membrane attack complex (MAC) formation C5 deficiency associated with minimal complications » » C3 Initiation » C1 C4 and C2 C3 Convertase Factor B C3bBb C3a C5 Convertase C4bC2a C3b C3bBbC3b Opsonization C4bC2aC3b Inflammation Complement C5 is clinically validated target Eculizumab is anti-C5 Mab Approved in PNH and aHUS Lectin Pathway C3 Susceptibility to increased Neisserial infections Many C5 deficient mouse strains Majority expressed in liver; circulates in plasma Classical Pathway Alternative Pathway C5a Terminal Pathway C5 C5b C5b-C9 In PNH, >80% inhibition of hemolytic activity associated with clinical benefit1 Membrane attack complex (MAC) Potential advantages of synthesis inhibition vs. protein binding approach 1Hillmen et al., NEJM; 350:552-9 (2004) 62 ALN-CC5 Hemolysis Inhibition and Clinical Efficacy Hemolysis inhibition to ~≤20% normal associated with clinical efficacy in PNH and aHUS No evidence that “>99.99%” hemolytic activity inhibition required Evidence of incomplete effects of eculizumab and loss of activity between IV doses PNH aHUS Incomplete effects of eculizumab Dosing: 900 mg every 14 days (subjects 1 & 2 required shorter interval of 12 days) Cugno et al., J Thromb Haemost; 10.1111/jth.12615 (2014) Serum C5 activity (%, sRBC hemolysis assay) Serum C5 activity (%, cRBC hemolysis assay) Hill et al., Blood;106:2559-2565 (2005) Loss of activity between eculizumab doses Weeks following last eculizumab infusion Dosing: 800 - 2000 mg 63 ALN-CC5 Pre-Clinical Efficacy Potent C5 Knockdown and Complement Activity Inhibition SC Administration of ALN-CC5 in non-human primates for over 7 months Potent dose-dependent C5 knockdown up to 99.2% » » Mean maximum knockdown of 98.4% ±0.7% Expect qM dosing regimen in humans based on translation of ESC-GalNAc-siRNA conjugates Potent inhibition of complement activity up to 96.9%; closely correlated with C5 knockdown » » Mean maximum inhibition of CAP ELISA of 95.1% ±0.93% Mean maximum inhibition of serum hemolytic activity of 88.0% ±6.1% Serum C5 -20 %Activity or hemolysis reduction %C5 Knockdown (Normalized to Pre-bleed) 0 20 40 60 80 Complement Activity (q2W) 0 2xw q2w qm CAP Hemolysis 20 40 60 80 100 100 0 20 40 60 2xW Regimen 80 100 120 140 160 180 200 220 Days q2W and qM Regimens 0 20 40 60 80 100 120 140 160 180 200 220 Days q2W Regimen Borodovsky, ASH, Dec. 2014 64 ALN-CC5 Phase 1/2 Study Dose-Escalation Study Including Patients with PNH Part A Part Study Design Randomized, double-blind, placebo-controlled SAD study in healthy volunteers (up to N=40) Primary Objective Safety and tolerability of single dose in healthy volunteers Secondary Objectives PK/PD and clinical activity C5 levels, hemolysis suppression Part B C Study Design Randomized, double-blind, placebo-controlled MAD study in healthy volunteers (up to N=24) Primary Objective Safety and tolerability of multi-dose in healthy volunteers Secondary Objectives PK/PD and clinical activity » C5 levels, hemolysis suppression Study Design Open-label MAD study in PNH patients (N=8) Primary Objective Safety and tolerability of multi-dose in PNH patients Secondary Objectives PK/PD and clinical activity C5 levels, hemolysis suppression, LDH reduction Status ESC-GalNAc-siRNA for SC dosing CTA filed; initiate Phase 1 early ’15 Initial data expected mid ’15 65 Clinical Development Plan ALN-CC5 for the Treatment of Complement-Mediated Diseases Broad-based development plan to maximize product opportunity Phase 1/2 Adult Healthy Volunteers and PNH patients Key Objectives • Safety, PK, and Clinical Activity (C5 knockdown and complement activity inhibition) • Initial Dose Finding and Extended Dosing (3-6 mo) • LDH Reduction in PNH Patients Phase 2 OLE PNH Patients Other Complement Mediated Diseases Phase 3 PNH aHUS MG NMO MN Pediatric (< 12 y.o.) 66 Acute Intermittent Porphyria (AIP) Program Unmet Need, Product Opportunity, and Program Status AIP is autosomal dominant disorder Ultra-rare orphan disease » » ~5,000 Patients with annual attacks U.S./EU ~500 Patients with recurrent attacks U.S./EU High unmet need and cost Patients present with acute or recurrent attacks Limited treatment options » » Blood-derived hemin given centrally No prophylactic treatment to prevent attacks Significant opportunity to treat and prevent porphyric attacks Orphan disease with substantial morbidity Value supported by significant burden of disease study ongoing » Prospective observational study of patients with hepatic porphyrias ALN-AS1 in R2D ESC-GalNAc-siRNA for SC dosing Proof of concept and efficacy in animal models DC selected CTA filing late ’14 67 Additional Genetic Medicine Programs AAT Deficiency Associated Liver Disease Commonest mutant allele (PiZZ) homozygosity results in liver cirrhosis » » Cell injury, ER stress, and autophagy resulting in fibrosis WW prevalence ~20,000 ALN-AAT targets alpha-1antitrypsin PiZZ allele Efficacy in pre-clinical animal models » >90% Knockdown of AAT; Reduction in fibrosis; reduced incidence of liver tumors IND mid ’15 Primary Hyperoxaluria Type 1 Loss of function mutations in liver peroxisomal alanine-glyoxylate aminotransferase (AGT) » Renal damage from increased oxalate, nephrocalcinosis, and renal obstruction ALN-GO1 targets glycolate oxidase (GO), enzyme upstream of AGT Efficacy in pre-clinical animal models » ~90% Knockdown of liver GO; ~80% Reduction in urinary oxalate DC mid ’15; IND ’16 Beta-Thalassemia and Iron-Overload Disorders Need for disease-modifying therapy to improve anemia and manage iron levels » >200,000 patients WW with thalassemia major; ~10,000 non-transfusion dependent patients U.S./EU ALN-TMP targets transmembrane protease, serine 6 (TMPRSS6) for hepcidin activation Efficacy in pre-clinical animal models showing disease-modifying effects » Results published in Blood 68 Genetic Medicine STAr Next Wave Target Assessment Large number of opportunities based on scientific, clinical, and market insights Target ID - Liver-expressed protein 100’s Targets “Next Wave” Triage Internal Validation External Validation • Literature review • Genetic medicine criteria • Preliminary prioritization • Scientific, clinical, and regulatory review • KOL Interactions Scientific Review Deprioritized Targets Primary prescriber unmet need assessment (if necessary) Commercial Review Discarded Targets 10’s Targets Target Validation • • • • In vitro and in vivo data generation Animal model / collaboration KOL panel Additional commercial assessment 69 Genetic Medicine STAr Summary (1/2) Significant opportunity for RNAi therapeutics as transformative medicines in rare diseases Potential to make meaningful impact on patient’s lives » Close connection to patients, caregivers, and providers Large number of genetically validated disease targets expressed in hepatocytes Reproducible and modular approach for rare disease platform » Unmatched in industry Emerging profile for ESC-GalNAc-siRNA highly attractive » Potent and durable, with very wide therapeutic index » Durability supports qM to qQ subcutaneous dose regimens » Best-in-class approach across industry 70 Genetic Medicine STAr Summary (2/2) Alnylam Genetic Medicine STAr advancing large number of programs Established human POC in 4 RNAi therapeutic programs » Includes active programs (patisiran, revusiran, and ALN-AT3) Patisiran and revusiran in Phase 3 trials for TTR amyloidosis » Both FAP and FAC to impact across entirety of disease spectrum ALN-AT3 in Phase 1 trial for hemophilia and rare bleeding disorders ALN-CC5 with filed CTA for complement-mediated diseases ALN-AS1 with CTA on track for YE ’14 in hepatic porphyrias ALN-AAT with IND in mid ’15 for alpha-1-antitrypsin deficiency liver disease Many clinical data read outs in 2015 and beyond Multiple additional pipeline programs, many undisclosed » Expect 1-3 INDs/year Alnylam plan to directly market and sell in NA and EU Pharmacoeconomics support value-based pricing model Genzyme partner for ROW and select 50-50 partner for certain programs in NA/EU » Expect >8 human POC from pipeline through end-2019 71 Pipeline Growth Strategy and Genetic Medicine STAr Q&A 72 Daniel Rader, M.D. Chair, Department of Genetics, Perelman School of Medicine, University of Pennsylvania 73 Cardiometabolic Disease: an Epidemic Insulin resistance Type 2 diabetes Inflammation Hypertension Dyslipidemia Fatty liver Cardiovascular disease Prevalence of obesity (% adults with BMI > 30) Body fat distribution Visceral fat Subcutaneous fat Obese Lean National Geographic; Aug 2004 Diseases associated with obesity Diabetes Dyslipidemia Hypertension Heart disease Stroke Sleep apnea Hypoventilation Asthma GERD NAFLD Gall stones Gout Osteoarthritis PCOS Infertility Thrombophlebitis Lymphedema Psoriasis Depression Pseudotumor cerebri Dementia Cancer (breast, endometrium, ovary, prostate, colon, esophagus, stomach, kidney, pancreas) Type 2 diabetes Chan J et al. Diabetes Care 1994;17:961; Colditz G et al. Ann Intern Med 1995;122:481. Coronary Heart Disease Folsom et al. Arch Intern Med 2000;160:2117. The Iowa Women’s Health Study Hospitalization Costs for Chronic Complications of Diabetes in the US Ophthalmic disease Renal disease Others Neurologic CVD accounts disease for 64% of total costs Peripheral vascular disease Total costs 12 billion US $ Cardiovascular disease American Diabetes Association. Economic Consequences of Diabetes Mellitus in the US in 1997. Alexandria, VA: American Diabetes Association, 1998:1-14. Dyslipidemia and coronary disease A-I B TG, CE CE LDL TG-rich lipoproteins Lp(a) HDL The Liver LDL Receptor regulates plasma LDL levels For illustration purposes only 81 81 PCSK9 is a liver-derived protein that regulates LDL uptake and is a major target for therapeutic inhibition For illustration purposes only 82 82 Triglyceride-rich lipoproteins are an important cause of cardiovascular disease B TG CE LPL CE B Multiple liver-derived proteins influence triglyceride metabolism B TG CE A-V LPL CE B C-III ANGPTL3 ANGPTL4 Non-alcoholic fatty liver disease (NAFLD) Adipose Liver Normal Steatosis Steatohepatitis Fibrosis (fatty liver) (inflammation and stellate cell activation) (collagen deposition) NASH Cirrhosis The Burden of NAFLD in the US Obese 90 million NAFLD 75 million NASH 12.5 million 0% 10% 20% 30% 40% AASLD guidelines 2012. US Census Bureau. Mortality in NAFLD 20% 18-year Mortality 17.5% 15% 10% 5% 2.7% Causes 1. CV 2. Cancer 3. Liver 0% NAFL NASH Rafiq, et al. CJH 2009; Ong, et al. J Hepatol 2008. Pathophysiology of NAFLD and Cardiometabolic disease Anstee, Nature Reviews Gastro and Hepatol 2013 The Liver is a Central Mediator of and Therapeutic Target for Cardiometabolic Diseases Hypertension AngiotensinRenin system NAFLD/NASH Cardiovascular Disease TGs FFAs Inflammation Gluconeogenesis Lipid Storage LDL/HDL Fructose LDL/HDL Clearance Type 2 Diabetes Insulin Resistance Glucotoxicity Glucose Nutrients Insulin GI Tract Retinopathy Nephropathy Neuropathy Pancreas Intra-abdominal Obesity Rachel Meyers, Ph.D. Vice President, Research and RNAi Lead Development Cardio-Metabolic Pipeline 90 91 Alnylam Development Pipeline Discovery Development Phase 1 Phase 2 Phase 3 GENETIC MEDICINES Patisiran (ALN-TTR02) TTR-Mediated Amyloidosis Revusiran (ALN-TTRsc) ALN-AT3 Hemophilia and Rare Bleeding Disorders ALN-CC5 Complement-Mediated Diseases ALN-AS1 Hepatic Porphyrias Alpha-1 Antitrypsin Deficiency ALN-AAT Beta-Thalassemia/Iron-Overload Disorders ALN-TMP Primary Hyperoxaluria Type 1 ALN-GO1 Additional Genetic Medicine Programs CARDIO-METABOLIC DISEASES ALN-PCSsc Hypercholesterolemia Mixed Hyperlipidemia/Hypertriglyceridemia ALN-ANG Hypertriglyceridemia ALN-AC3 Hypertension/Preeclampsia ALN-AGT Additional Cardio-Metabolic Programs HEPATIC INFECTIOUS DISEASES Hepatitis B Virus Infection ALN-HBV Hepatitis D Virus Infection ALN-HDV Chronic Liver Infection ALN-PDL Additional Hepatic Infectious Disease Programs Alnylam Development Pipeline Discovery Development Phase 1 Phase 2 Phase 3 Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-TMP ALN-GO1 CARDIO-METABOLIC DISEASES ALN-PCSsc Hypercholesterolemia Mixed Hyperlipidemia/Hypertriglyceridemia ALN-ANG Hypertriglyceridemia ALN-AC3 Hypertension/Preeclampsia ALN-AGT Additional Cardio-Metabolic Programs ALN-HBV ALN-HDV ALN-PDL Alnylam RNAi Therapeutics Strategy A Reproducible and Modular Path for Innovative Medicines 2. POC achieved in Phase 1 Blood-based biomarker with strong disease correlation GCCCCUGGAGGG » e.g., Serum TTR, thrombin generation, hemolytic activity, LDL-C, HBsAg levels 3. Definable path to approval and market 1. Liver-expressed target gene Involved in disease with high unmet need Validated in human genetics GalNAc-siRNA enables SC dosing with wide therapeutic index Established endpoints Focused trial size Large treatment effect Collaborative approach with physicians, regulators, patient groups, and payers 94 Emerging Profile for RNAi Therapeutics Cardio-Metabolic Disease Emerging profile for ESC-GalNAc-siRNA conjugates Attractive pharmacologic properties » » » » Subcutaneous dose administration High potency with microgram/kg (mcg/kg) doses Low volume per injection, <1 mL Durability for monthly (qM) and possibly quarterly (qQ) dose frequency Competitive profile with RNAi mechanism » Block synthesis of disease-causing protein » Efficacy independent of target protein blood levels » Clamped knockdown with low inter-individual variability Well tolerated and wide therapeutic index Unique opportunity for cardio-metabolic disease Growing human genetics data expands accessible target space » Large populations continue to be genetically segmented Potential to address more common diseases impacting millions of people Improved compliance expected due to infrequent dosing Dual-targeting possible 95 Human Liver Central Mediator of Multiple Inter-Related Cardio-Metabolic Diseases Hypertension AngiotensinRenin system NAFLD/NASH Cardiovascular Disease TGs FFAs Inflammation Gluconeogenesis Lipid Storage LDL/HDL Fructose LDL/HDL Clearance Type 2 Diabetes Insulin Resistance Glucotoxicity Glucose Nutrients Intra-abdominal Obesity Insulin GI Tract Retinopathy Nephropathy Neuropathy Pancreas 96 Dyslipidemia Key Risk Factor in Cardiovascular Disease Dyslipidemia Pathophysiology and Disease Burden Key Contributors » Genetic factors, obesity, poor nutrition, physical inactivity Cardiovascular disease leading cause of mortality in U.S. Dyslipidemia patient population growing rapidly, outpacing population growth Altered Lipid Metabolism Intestinal Tract Abnormal Lipid Profile LDL Triglycerides HDL Adipocytes CDC, America’s Cholesterol Burden 2012; Heidenreich, 97 Circulation. 2011;123(8):933; KOL Interviews ALN-PCSsc Program and PCSK9 Unmet need in hypercholesterolemia Elevated LDL-C validated risk factor for CVD 34 million Americans have hypercholesterolemia (> 240 mg/dL) Recent clinical studies » » Many patients on statins do not meet LDL-C goal Lower LDL-C is better Multiple genetically defined patient subgroups PCSK9 is a genetically validated target GOF mutations associated with hypercholesterolemia and premature CHD LOF mutations associated with hypocholesterolemia and decreased CHD risk CHD Risk WT PCSK9 12 30 Coronary Heart Disease (%) 20 10 Frequency (%) 0 30 LOF PCSK9 20 10 0 8 4 0 50 100 150 200 250 300 WT LOF Plasma LDL Cholesterol (mg/dl) Pearson et al., L-TAP Study, Arch Intern Med; 160:459-67 (2005), Blazing e al Am. Heart J; 168:205 (2014) 98 Cohen et al., N. Engl. J. Med.; 354:1264-1272 (2006) PCSK9 Therapeutic Hypothesis LDL MAbs are PCSK9 blockers Endosome RNAi therapeutics are PCSK9 synthesis inhibitors Catalytic degradation of PCSK9 mRNA – independent of plasma levels Bind 1:1 to PCSK9 protein – sensitive to plasma levels Lysosomal degradation LDLR synthesis PCSK9 synthesis PCSK9 ALN-PCSsc PCSK9 mRNA Nucleus 99 ALN-PCS02 Phase 1 Study Results Pharmacodynamics and Clinical Efficacy PCSK9 knockdown and LDL-C reduction after single dose without statins Randomized, placebo-controlled, single dose escalation study » Healthy volunteers with elevated LDL (n=32) Rapid, dose-dependent, and durable knockdown of PCSK9 of up to 84% with mean lowering of 68% at 0.4 mg/kg group (p<0.0001) Major reductions in LDL-C of up to 50% with mean lowering of 41% at 0.4 mg/kg group (p<0.01) PCSK9 Mean Relative to Baseline and Placebo % Knockdown PCSK9 Plasma Levels -40 LDL-C -20 0 20 40 60 ALN-PCS dose group (mg/kg) 80 0.015 0.045 0.090 100 siRNA Dose 0.150 0.250 0.400 % Reduction LDL-C Mean Relative to Baseline and Placebo -20 0 20 ALN-PCS dose group (mg/kg) 40 0.015 0.045 0.090 0.150 0.250 0.400 60 5 10 15 Days 20 25 siRNA Dose 5 10 15 Days 10 Fitzgerald et al., The Lancet (2013) 0 20 25 ALN-PCSsc Pre-Clinical Efficacy in NHP Potent PCSK9 Knockdown and LDL-C Lowering: Single Dose Data Highly durable PCSK9 knockdown and LDL-C reduction with single dose Single SC dose 1-10 mg/kg Up to 96% PCSK9 knockdown, up to 77% LDL-C lowering; absence of statins Highly durable effects, supports once-monthly or possibly once-quarterly dosing » >50% LDL-C lowering maintained for over 3 months in 10 mg/kg group PCSK9 LDL-C 1.0 3.0 6.0 10.0 1.0 3.0 6.0 10.0 -20 % LDL-C Lowering (relative to pre-bleed) % PCSK9 Knockdown (relative to pre-bleed) -20 0 20 40 60 80 0 20 40 60 80 100 100 0 ALN-PCSsc (mg/kg) 20 40 Days 60 80 100 0 ALN-PCSsc (mg/kg) 20 40 60 Days Fitzgerald, AHA, Nov 2014 10 1 80 100 120 ALN-PCSsc Pre-Clinical Efficacy in NHP Potent PCSK9 Knockdown and LDL-C Lowering: Multi-Dose Data Potent and stable PCSK9 knockdown and LDL-C lowering with monthly SC dosing » 6 mg/kg 1st dose, 3 mg/kg monthly maintenance Up to 92% PCSK9 knockdown, up to 77% LDL-C lowering; absence of statins Clamped knockdown of PCSK9 and reduction in LDL-C levels with monthly maintenance dosing for over 6 months -40 LDL-C PCSK9 -20 (Relative to pre-bleed) Monthly SC dose regimen % PCSK9 Knockdown and LDL-C Lowering 0 20 40 60 80 100 0 20 40 60 80 100 120 140 160 180 200 Days Fitzgerald, AHA, Nov 2014 10 2 ALN-PCSsc Versus Anti-PCSK9 MAbs Potential Differentiation Differentiation for ALN-PCSsc Rebound in LDL-C with qM dosing for anti-PCSK9 MAb Clamps PCSK9 knockdown and LDL-C lowering with monthly or, possibly quarterly SC dosing » Independent of baseline or fluctuating PCSK9 levels Potential for synergy with statins » Statins upregulate PCSK9 and compromise MAb efficacy McKenney et. al., JACC, 59, No.25, 2012 10 3 ALN-PCSsc Phase 1 Study Study Design Randomized, single-blind, placebo-controlled, single ascending dose (SAD) and multi-dose (MD), subcutaneous dose-escalation study Up to 76 volunteer subjects with elevated baseline LDL-C (≥100 mg/dL) » MD phase to also include subjects both on and off statin co-medication 3:1, ALN-PCSsc vs. placebo Treatment Regimen SD or MD (qM x 2) Study Objectives Primary: safety and tolerability of ALN-PCSsc Secondary: PK, clinical activity (% reduction of LDL-C and knockdown of PCSK9 compared to baseline) Status Phase 1 started Initial clinical data expected mid-2015 104 APOC3 Validated Liver Target for Reduction of TG Levels Unmet need in hypertriglyceridemia >50M in U.S. have high triglycerides (>200 mg/dL) » >3M have very high triglycerides (>500 mg/dL) Additional opportunity in ultra-rare orphan condition in people lacking properly functioning lipoprotein lipase (LPL) » ~1,000 Patients with Familial Chylomicronemia Syndrome VLDL TG hydrolysis APOC3 inhibits lipoprotein lipase to prevent triglyceride hydrolysis Loss-of-function individuals have lower triglyceride levels, lower rates of coronary artery calcification, and CVD risk Pro-inflammatory effects on vascular endothelium Primarily expressed in liver Crosby NEJM 371:22 (2014) Pollin, Science 322(5908):1702-5 (2008) LPL APOC3 IDL TG hydrolysis LDL 105 HTGL ALN-AC3 Targeting ApoC3 Potent ApoC3 Knockdown and TG Lowering ALN-AC3 inhibits ApoC3 and reduces triglycerides 94% reduction of human serum ApoC3 at 3 mg/kg » Durable effect Human ApoC3 Protein -20 0 20 40 60 80 100 0 10 ALN-AC3 q2W x 5 20 30 40 Days 50 Triglyceride Lowering 1.0 % TG Lowering (Relative to Pre-dose) % ApoC3 Knockdown (Relative to Pre-dose) Up to 50% lowering of triglycerides in db/db mouse model of hyperlipidemia 60 70 0.8 0.6 0.4 1.25 mg/kg 2.5 mg/kg 5.0 mg/kg 0.2 0.0 0 5 10 ApoC3-GalNAc qD x 5 Fitzgerald, ATVB, May 2014 15 Days 106 20 25 ANGPTL3 Validated Liver Target for Reduction of TG and LDL-C Levels ANGPTL3 is genetically validated target Functions as lipase inhibitor Loss of function ANGPTL3 mutations associated with combined hypolipidemia » Increased LPL activity, increased insulin sensitivity » Extremely low LDL-C, HDL-C, and triglycerides » Decreased free fatty acids LDL-C Triglycerides Musunuru et al., NEJM (2010) Koishi, et al., Nat Gen (2002) 107 ALN-ANG Targeting ANGPTL3 Efficacy in Rodent Models ALN-ANG inhibits ANGPTL3 and reduces circulating lipids in ob/ob mice Up to 99% lowering of serum ANGPLT3 Up to 80% reductions in triglycerides and LDL-C -40 -20 -20 0 20 40 60 80 10 15 0 20 40 60 80 100 100 5 (Relative to PBS) -40 % LDL Lowering 50 (Relative to PBS) % TG Knockdown 0 100 0 LDL-C Triglycerides -50 (Relative to Pre-dose) % ANGPTL3 Knockdown ANGPTL3 Knockdown 0 5 10 15 0 5 Days Days PBS ALN-ANG, 0.3mg/kg 10 Days ALN-ANG, 1mg/kg ALN-ANG, 3mg/kg Fitzgerald, AHA, Nov 2014 108 15 Hypertension (HTN) Significant Unmet Needs in Specific Populations Highly prevalent disease Angiotensinogen » Compliance is area of high unmet need High unmet need in preeclampsia for safe and effective therapy » >500,000 U.S./EU pregnancies complicated by hypertension » Preeclampsia in >200,000/year – – 10-20% of maternal or fetal perinatal deaths Premature delivery associated with neonatal intensive care, risk of morbidity and mortality Opportunity for RNAi therapeutic targeting angiotensinogen in maternal liver » Pharmacologically validated pathway » Control hypertension, preeclamptic symptoms » Maintain pregnancy, extend gestation, and avoid premature delivery » RNAi therapeutic does not cross placenta, avoiding fetal exposure Renin Inactive Peptide Inactive Peptide Angiotensin I ACE, chymase, carboxypeptidase, tonin, cathepsin C NEP Natriuretic peptides Bradykinin BKR Angiotensin II AT2R NO AT1R Aldosterone Vasodilation Anti-fibrosis Apoptosis Natriuresis Anti-inflammation Modified from Paulis & Unger Nat. Rev. Cardiol. 7, 431–441 (2010) Vasconstriction Collagen synthesis Anti-apoptosis ROS generation + Na and water retention 109 (P)RR ALN-AGT Pre-clinical Efficacy in Model of Preeclampsia ALN-AGT improves maternal preeclamptic symptoms without fetal exposure >90% Silencing maternal AGT » No fetal exposure of drug » » >80% reduction in proteinuria >75% reduction in maternal VEGF receptor-1 (FLT1) Improves hypertension with ~20 mmHg decrease in mean arterial pressure Improves preeclamptic symptoms Significant improvements in fetal outcomes 30 Albuminuria 4 Fetal Weight 100000 Tissue Exposure 20 10 0 ng siRNA/g tissue Fetal Weight (g) Albuminuria (mg/dL) 10000 3 2 1 PE RNAi 100 10 25,712 97 <LLOD 1 0.1 0 PE Control 1000 PE Control PE RNAi Maternal Liver 110 Placenta Fetal Liver NASH Unmet Need and Program Opportunity NASH is progressive fibrotic liver disease Leads to cirrhosis and liver failure ~1M diagnosed patients in U.S. » NASH growth >> population growth – Fueled by expansion of metabolic co-morbidities » Availability of therapy and novel diagnostics will expand diagnosed patients in future – Estimated ~3M patients by 2030 Third most common cause of liver transplantation in U.S., and growing Therapeutic options needed Currently no approved therapies Several agents in development but unmet needs will remain Number of liver targets for RNAi therapeutics Multiple Alnylam opportunities being pursued Charlton. Gastroenterology. 141:1249 (2011;) Bellentani. Ann Hepatol. 8(1):S4; (2009) Younossi. Clin Gastroenterol Hepatol.;9(6):524 (2011) 111 Type 2 Diabetes Unmet Need and Program Opportunity Type 2 Diabetes one of fastest growing health burdens in established markets Insulin Resistance WW prevalence ~370M by 2030 » ~$245B costs in U.S. in 2012 Glucose Production by Liver Multiple disease complications Glucose Uptake in Muscles » Increased CV risk, renal disease, retinopathies, neuropathies Growth due to aging population, lifestyle choices, co-morbid conditions Blood Glucose Opportunity clearly defined Novel therapeutics should deliver demonstrable “dual benefit” Glucose control plus other benefit, such as weight loss Number of liver targets for RNAi therapeutics Multiple Alnylam opportunities being pursued » Includes dual-targeting Beta-cell Dysfunction Insulin Production Genetic Factors, Obesity, Nutrition, Physical Inactivity Boyle. Popul Health Metr 8:29; (2010); American Diabetes Association The Cost of Diabetes, (2012) 112 Cardio-Metabolic Disease STAr Summary (1/2) Significant opportunity for RNAi therapeutics as transformative medicines in cardio-metabolic diseases High unmet medical need in multiple patient segments » Dyslipidemia, hypertension, NASH, and type 2 diabetes Many important hepatocyte-expressed targets Increasing power of human genetics fueling more opportunities Emerging profile for ESC-GalNAc-siRNA highly attractive » Potent and durable, with very wide therapeutic index » Durability supports qM to qQ subcutaneous dose regimens » Ability to achieve dual targeting 113 Cardio-Metabolic Disease STAr Summary (2/2) Alnylam Cardio-Metabolic Disease STAr advancing multiple programs Established human POC with RNAi therapeutics » ALN-PCS02: robust knockdown of PCSK9 and reduction of LDL-C in Phase 1 study ALN-PCSsc in Phase 1 trial for hypercholesterolemia » Initial data expected in mid ’15 » Partnered with The Medicines Company Additional programs in development for dyslipidemia and hypertensive disorders of pregnancy » Includes ALN-AC3, ALN-ANG, and ALN-AGT Multiple additional pipeline programs » Expect ~1 IND/ year Represents new opportunities for partnership Alnylam to retain meaningful product rights in core markets Leverage partner for expanded effort and geographic scope 114 Cardio-Metabolic Disease STAr Q&A 115 BREAK Welcome Back Timothy Block, Ph.D. President, Hepatitis B Foundation of America and its Baruch S. Blumberg Institute, and Professor, Drexel University College of Medicine 118 Is a Cure for Hepatitis B Possible? Necessary? Tim Block, Ph.D. Is a Cure for Hepatitis B Possible? Necessary? • • • • • The problem of hepatitis B and liver cancer Limits of current therapies for managing HBV Rationale for new strategies Summary of Experimental Strategies Defining a cure 120 Shocking epidemiology: 350 million chronic carriers 350 million people with chronic HBV HBsAg Prevalence >=8% - High 2-7% - Intermediate <2% - Low Medical Management of Chronic Hepatitis B (CHB) 122 Timeline of Approved Drugs for Chronic HBV REVEAL Study: The Relationship Between Virus Number and Hepatocirrhosis/Hepatocellular Carcinoma 4006 Study: antiviral therapy could slow down the development of CHB 1992 Interferon approved for CHB 1998 Lamivudine 2002 Adefovir 2004 2005 2006 2007 2008 Entecavir PEG-IFN Tenofovir Telbivudine Tenofovir approved in US for HBV, in 2008, but not yet approved in China for HBV 123 7 Medications for Chronic HBV Management • The IFNs • The polymerase inhibitors Treatment Guidelines for the Management of CHB HBeAg + Recommendation Group HBeAg - DNA ALT DNA ALT genomes/mL x ULN genomes/mL x ULN AASLD 105 >2 104 >2 Lok & McMahon 2007 US Panel 105 >1 104 >1 Keefe 2006 EASL 105 >2 105 >2 deFranchis 2002 Asia-Pacific 105 >2 104 >2 Liver Int 26:47-58 Reference So, what’s the problem? 124 China 120 Million Chronic HBV Carriers ~50 Million within Treatment Guidelines ~8M Treated 125 USA 1.2-2 Million Chronic HBV Carriers ~500-800,000 within Treatment Guidelines ~75,000 Treated 126 10 Year Liver Mortality (%) HBsAg+, Negative Family History, No Alcohol 100 90 80 Treatable 70 (HBeAg+, abn ALT) 60 50 40 30 “Untreatable” 20 (HBeAg-, nl ALT) 10 0 30 40 50 60 Age in years A. Evans, 2012 127 Antiviral Therapy for Chronic HBV Infection and Development of Hepatocellular Carcinoma in USA • Analyzed electronic health records of 2671 adult participants in the Chronic Hepatitis Cohort Study (CHeCS) diagnosed with chronic HBV infection from 1992 through 2011 – Crude HCC incidence rate was 4.2 cases/1000 person years • 67/2671 patients developed HCC over follow-up period (3%) • 20/820 cases in the group receiving treatment (2.4%) • 47/1851 cases occurred in the untreated group (2.5%) aHR 0.50; 95% CI 0.350.72; p < 0.001 – After adjustments for matched pairs/subgroups analysis: • treatment vs. no treatment: aHR 0.39; 95% CI 0.27-0.56; p <0.001 • treatment vs. no treatment matched by serum markers for cirrhosis: aHR 0.24; 95% CI 0.15-0.39; p <0.001 (no interaction noted between treatment and fibrosis markers) • treatment vs. no treatment matched by HBV-DNA/ALT when viral load >20,000 IU/ml: aHR 0.17; 95% CI 0.06-0.52; p=0.002 – 10 year Rx reduces cancer deaths by 50% (Lok, 2013) Gordon SC et al Clin Gastro & Hep 2014 http://dx.doi.org/10.1016/j.cgh.2013.09.062 128 Why? 129 Even After Years of Rx Chevaliez et al 2012 J Hepatology Zoulim et al, Gastro.2004; 48 wk ADF 130 Nests of infected cells (cccDNA containing) remain 131 Defining a Cure: Goals • Clinically: returning a chronic hepatitis B carrier to the level of risk of death due to liver disease of someone with a resolved infection • Functionally: enduring suppression of all measurable viral markers (antigenemia and viremia) and restoration of humoral sAb 132 Need • Something new that complements current compounds • An immuno-enhancer 133 Landscape of New Rx • What is in human trials, now? • What is at the pre-human trial stage? 134 Experimental HBV Therapeutics in Clinical Trials In vitro AGX1009 prodrug-ten optimized Animal efficacy Gilead Yeast Immune Compl Cap Med U, Beijing, insufficient efficacy Elvucitabine pol inhib Achillion CYT107 IL-7 Phase 3 Arrowhead Cytheris SA, discontinued, results unknown MIV 210 pro-drug Medivir, Discontinued Besifovir pol inhibi Idong, Discontinued Isis HBV-Rx antisense Isis MycB entry inhibitor Gmb NVR1221 capsid inhibitor Novira GS-4774; vaccine Gilead GS9620 Toll7 Gilead DV601 Vac+nuc acid adj Dynavax RepA9 sAg inhibitor Replicor BAY41-109 capsid Phase 2 Agenix/SHRG/YSY GS-7340 prodrug-ten ARC 520 (RNAi) Phase I AiCuris DAA: Indirect: 135 Experimental HBV Therapeutics in Preclinical Development In vitro OCB-030/NVP019 CMX157 prodrug ten TKM HBV Tekmira ddRNAi- Benitec Briniprint/SMAC Tetralogic GLS-4 capsid Sunshine Innovio Altravax HBV Altravax Capsid Inhibitor (2 Programs) OnCore S Antigen Secretion Inhibitor OnCore Phase 3 Blumberg/Drexel Editope Blumberg Capsid Inhibitor Assembly STING Agonist OnCore* OnCore HDAC OnCore* Chimegene Therapeutic Vaccine Akshaya H- Tropolones RNaseH Phase 2 Agenix Inv-HBV cccDNA Formation Inhibitors Phase I Chimerix Alnylam DVR-pregrna Animal efficacy Oncore/Neurovive ALN HBV AGX 1009 prodrug ten Optimized St. Louis U * In collaboration with the Blumberg Institute 136 Categories of Anti-HBV Strategies Direct Acting Antivirals • In Use – Polymerase • Potential – – – – – – – RNaseH RNAi Capsid inhibitors sAg eAg Virus attachment CRISPR/CAS In-Direct Acting Antivirals Immuno-modulatory • In Use – • – Interferons Potential – – – – Essential host functions • In Use • Therapeutic vaccines Toll R agonists STING, other innate defense Interleukins, other cytokines None for HBV Potential – – – – – Epigentic modifiers Entry Morphogenesis Exit Glycan processing 137 The HBV Therapeutic Development Landscape as of October, 2014 Pre-clinical DAA TTP sAg DVR capsid cccDNA forma Indirect Host modifier Human Phase Trials AGX1009 prodrug GLS-4 capsid CMX157 prodrug Benza capsid TKM-HBV CpAMS capsid ALN- HBV Isis HBV antisense ARC520 RNAi NVR122 1 capsid Bay4110 9 capsid GS7340 Pro-ten MycB entry RepA9 sAg ddRNAi HBV NV100 Editope Briniprin t SMAC HDAC Indirect Immunomodulator Chimgene HBV STING Altravax HBV Inovio HBV GS4774 vac DV501 Vac GS9620 Toll 138 Conclusions • Goal of therapy: return those with chronic B to the level of risk of people with resolved infections • New medications will be needed to do this • At least 12 steps in the virus life cycle can be targeted • cccDNA is regulated differently than integrated HBV, and can be repressed and degraded • Pharmacological activation of neighboring non hepatocyte cells could be a means of inducing sterilization of hepatocytes of HBV 139 A cure is possible A cure is necessary 140 Acknowledgments • Drexel University – Jinhong Chang, Ju-Tao Guo, Fang Guo, Xuessen Zhao, Fei Liu, Pinghu Zhang, HaiTao Guo, David Cai • The Baruch S. Blumberg Institute, Hepatitis B Foundation – Andy Cuconati, Yanming Du, Michael Xu, Michael Goetz, Matt Campang, Bill Kinney • Support from: The US NIH, NIAID, NCI and The Hepatitis B Foundation and Commonwealth of Pennsylvania 141 Laura Sepp-Lorenzino, Ph.D. VP, Entrepreneur-in-Residence and Program Leader Hepatic Infectious Disease Pipeline 142 143 Alnylam Development Pipeline Discovery Development Phase 1 Phase 2 Phase 3 GENETIC MEDICINES Patisiran (ALN-TTR02) TTR-Mediated Amyloidosis Revusiran (ALN-TTRsc) ALN-AT3 Hemophilia and Rare Bleeding Disorders ALN-CC5 Complement-Mediated Diseases ALN-AS1 Hepatic Porphyrias Alpha-1 Antitrypsin Deficiency ALN-AAT Beta-Thalassemia/Iron-Overload Disorders ALN-TMP Primary Hyperoxaluria Type 1 ALN-GO1 Additional Genetic Medicine Programs CARDIO-METABOLIC DISEASES ALN-PCSsc Hypercholesterolemia Mixed Hyperlipidemia/Hypertriglyceridemia ALN-ANG Hypertriglyceridemia ALN-AC3 Hypertension/Preeclampsia ALN-AGT Additional Cardio-Metabolic Programs HEPATIC INFECTIOUS DISEASES Hepatitis B Virus Infection ALN-HBV Hepatitis D Virus Infection ALN-HDV Chronic Liver Infection ALN-PDL Additional Hepatic Infectious Disease Programs Alnylam Development Pipeline Discovery Development Phase 1 Phase 2 Phase 3 Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-TMP ALN-GO1 ALN-PCSsc ALN-ANG ALN-AC3 ALN-AGT HEPATIC INFECTIOUS DISEASES Hepatitis B Virus Infection ALN-HBV Hepatitis D Virus Infection ALN-HDV Chronic Liver Infection ALN-PDL Additional Hepatic Infectious Disease Programs Alnylam RNAi Therapeutics Strategy A Reproducible and Modular Path for Innovative Medicines 2. POC achieved in Phase 1 Blood-based biomarker with strong disease correlation GCCCCUGGAGGG » e.g., Serum TTR, thrombin generation, hemolytic activity, LDL-C, HBsAg levels 3. Definable path to approval and market 1. Liver-expressed target gene Involved in disease with high unmet need Validated in human genetics GalNAc-siRNA enables SC dosing with wide therapeutic index Established endpoints Focused trial size Large treatment effect Collaborative approach with physicians, regulators, patient groups, and payers 146 Emerging Profile for RNAi Therapeutics Hepatic Infectious Disease Emerging profile for ESC-GalNAc-siRNA conjugates Attractive pharmacologic properties » » » » Subcutaneous dose administration High potency with microgram/kg (mcg/kg) doses Low volume per injection, <1 mL Durability for monthly (qM) and possibly quarterly (qQ) dose frequency Competitive profile with RNAi mechanism » Block synthesis of disease-causing protein » Efficacy independent of target protein blood levels » Clamped knockdown with low inter-individual variability Well tolerated and wide therapeutic index Unique opportunity for hepatic infectious disease Pathogen genomics informs selection of highly conserved, pan-genotypic RNAi therapeutics Combination approach feasible Infrequent dosing expected to yield improved compliance Room temperature stability enables global deployment Short R&D timelines enable rapid identification of RNAi therapeutics for emerging global infectious diseases 147 Hepatic Infectious Diseases Strategic Considerations Hepatic Infectious Diseases Primarily involve liver • Hepatitis viruses: A, B, C, D, E Have obligate liver stage • Malaria Major liver involvement in disease • Filoviruses (Ebola, Marburg) and other hemorrhagic viruses Infection occasionally causes severe liver disease • Herpesviruses: HSV, EBV, CMV • Adenoviruses 148 Hepatic Infectious Diseases Programs and Target Opportunities Pathogen Targets RNA viral genomes, replication intermediates, viral transcripts Host Factors Subverted to support pathogen lifecycle; Non essential to host Immune Modulators Immune evasion 149 Hepatic Infectious Diseases Programs and Target Opportunities HBV HDV HEV Others Pathogen Targets RNA viral genomes, replication intermediates, viral transcripts Host Factors Subverted to support pathogen lifecycle; Non essential to host Immune Modulators Immune evasion 150 Hepatitis B Virus (HBV) Infection Chronic HBV (CHB) infection is significant WW problem One third of world population infected 400M people with chronic disease » 25M in U.S./EU Most unaware of infection High prevalence expected for next 3 decades » Despite availability of HBV vaccine Clinical manifestations severe Chronic inflammation leading to cirrhosis and HCC Current therapies not curative and have significant limitations Reduce viral load, resulting in improved liver histology, decrease in cirrhosis and HCC but do not eliminate virus Future therapies aim to enable “functional cure” Regain sustained immune control over infection, with eventual elimination of virus’ cccDNA http://www.hepb.org/hepb/statistics.htm 151 Novel CHB Therapies Aim to Cure Goal: Enable Functional Cure Achieve state of immunological control of infection » HBsAg sero-clearance and sero-conversion Prevent progression of disease to cirrhosis, liver failure or HCC Clearance of circulating viral DNA, normalization of ALT and histology Inhibit Viral Lifecycle Therapeutic Strategies Reduce circulating virus and inhibit new/re-infection Entry, nucleocapsid assembly, cccDNA maintenance inhibitors complement novel reverse transcriptase inhibitors (NUCs) Silencing of viral transcripts Reduce Tolerogenic Proteins HBsAg secretion inhibitors Knockdown of HBsAg and HBeAg Break Immune Tolerance Boost immune response to aid in clearing virus TLR7 agonist, therapeutic vaccines, immune checkpoint inhibitors Knockdown of PD-L1 152 HBV Targeting with RNAi Therapeutics Compact Genome Provides Multiple Opportunities Genome structure 2 3.2 kb partially double stranded DNA genome Replication occurs through RNA intermediate 4 overlapping viral transcripts encoding 7 viral proteins translated across 3 reading frames 3 1 siRNA targeting 0.7 kb region which overlaps across 4 transcripts 1.4 kb region which overlaps across 3 transcripts 4 Depending on location, single siRNA could silence 1 to 4 transcripts Kidd-Ljunggren K, J Gen Virol 83:1267–1280 (2002) 153 RNAi Therapeutics for HBV HBV-Infected Chimpanzees (1/3) Sequence-specific antiviral response following single dose Viral titers up to 1010 copies /mL >2 log10 reduction in circulating viral DNA in highest titer animal Mean 1.9 log10 decrease in viral DNA day 2- 6 post dose Control siRNA-LNP confirms specificity Absolute Titer Normalized Titer Control siRNA-LNP 0.25 mg/kg IV Δ Viral Load (log10 copies/ml) (copies/mL plasma) 10 10 10 9 10 8 10 7 HBV siRNA-LNP 0.25 mg/kg IV 1 Control siRNA-LNP 0.25 mg/kg IV 0 (relative to day 0) HBV siRNA-LNP 0.25 mg/kg IV 10 11 Plasma viral DNA -1 -2 10 4 10 3 -3 0 20 40 60 Days 80 100 0 20 40 60 80 Days BLOQ = determinations were below the lower level of quantitation Meyers, TIDES, May 2014 154 A C B D 100 RNAi Therapeutics for HBV HBV-Infected Chimpanzees (2/3) Dose-dependent antiviral response with intra-subject ascending doses Mean 2.9 log10 decrease in viral DNA day 2- 6 post 0.5 mg/kg dose » >4 log10 reduction in circulating viral DNA achieved in highest titer animal Mean 2.0 log10 reduction in HBsAg at 0.5 mg/kg dose » Up to 2.3 log10 reduction achieved Plasma HBsAg (Surface Antigen) Plasma Viral Load (bDNA) siRNA (mg/kg) siRNA (mg/kg) 0 log10 Δ HBsAg -1 -2 -3 -4 A C* B D -5 -20 0 20 40 60 80 100 120 140 160 Days (relative to average of pre-dose values) Log10 Δ Viral Load (relative to average pre-dose) 0.125 0.25 0.50 0.125 0.25 0.50 1 0 -1 -2 -3 -20 0 20 40 60 80 Days *low titer animal dropped below LLOQ from day 23-day 98 Meyers, TIDES, May 2014 155 A C B D 100 120 140 160 RNAi Therapeutics for HBV HBV-Infected Chimpanzees (3/3) Potential evidence for therapeutic flare ALT normalized in highest titer chimp Possible therapeutic immune flare in 2/4 chimps » Correlated with small increases in IL6 and IFNg siRNA (mg/kg) 0.125 600 0.25 0.50 A C B D High baseline ALT reversed with siRNA treatment ALT(U/L) 400 2x ALT increase consistent w/ therapeutic immune flare 200 0 -20 0 20 40 60 80 100 Days Meyers, TIDES, May 2014 156 ALN-HBV Target Product Profile Functional Cure of CHB ALN-HBV Target Product Profile Indication • Chronic hepatitis B (CHB) treatment – enable functional cures Dose and Regimen • <150 mg fixed dose, monthly for 12-24 months alone or in combination with standard of care Route of Administration • Subcutaneous injection, < 1 mL injection volume, self-administration with auto-injector device, room temperature stability Efficacy • Achieve functional cure as defined by HBsAg sero-clearance and HBsAb sero-conversion Safety • <1% incidence of drug discontinuation • No black box warning • Well tolerated, including in combination with immune-modulator therapy 157 GalNAc-Conjugates as Anti-Viral Approach Clinical Validation Regulus RG-101 » GalNAc-anti miR122 in development for HCV Clinical activity » Single 2 mg/kg SC dose demonstrated potent and sustained viral load reduction RG-101 well tolerated 158 ALN-HBV Lead Optimization Iterative Approach to Fine-Tune siRNA Chemistry Multiple siRNAs selected targeting 3 and 4 viral transcripts with high degree of conservation across genotypes (A-H) (>94%) Enhanced Stabilization Chemistry (ESC) Superior activity Template Design Design of SAR set In vitro metabolic stability Inferior activity (GalNAc)3 5′-sense 5′-antisense siRNA synthesis Chemistry optimization at each position AD-65381 IC50 0.0193 In vitro Potency Liver/plasma PK RISC loading HBV efficacy models (GalNAc)3 5′-sense 5′-antisense Exploratory Rat toxicology Lead Candidate Target remaining (% of F7) 120 105 90 75 60 45 30 15 0 -7 1x10 Sepp-Lorenzino, AASLD, Nov. 2014 0.0001 0.1 Concentration(nM) 159 100 ALN-HBV Development Candidate (DC) Selected Potent ESC-GalNAc-Conjugate for IND in Late ’15 Potent, multi-log HBsAg knockdown of ALN-HBV DC in murine model » Up to 3.9 log10 reduction; mean 1.8 log10 reduction 5-10 days after single dose Specificity confirmed with control siRNA DC selection achieves 2014 goal; IND filing expected in late ’15 ALN-HBV 1000 Control siRNA 1000 100 100 HBsAg (ng/mL) Mouse model with AAV-HBV vector Single SC dose of siRNA at 3 mg/kg ALN-HBV DC achieves potent knockdown of HBsAg HBsAg (ng/mL) 10 1 0.1 10 1 0.1 Each line represents individual animal 0.01 0.01 0 Days 5 10 Each line represents individual animal 0 Days 5 10 160 Hepatitis D Virus (HDV) Infection HDV is highly pathogenic, resulting in aggressive hepatitis RNA subvirus, which can only propagate in presence of HBV 15-20M patients infected WW » 80K patients in U.S. Acquired at same time or subsequent to HBV infection » >90% of latter patients develop chronic disease (CHD) Chronic HBV/HDV infection more aggressive than CHB » 3x greater rates of cirrhosis occurring earlier (70-80% of cases within 5-10 yr) » 10x higher mortality rates No Data Very Low High 15-20M patients infected WW Gish, et al J Gastroenterol Hepatol. (2013); Farci & Niro, Semin Liver Dis., (2012); Ciancio & Rizzetto, Nature Reviews Gastroenterology & Hepatology (2014); http://hepatitis-delta.org/ 161 RNAi Therapeutics for HDV Treatment RNAi therapeutics for HDV represent compelling market opportunity L-sAg M-sAg HBsAg HBV Gene Products HDV RNA No curative therapies available HDV Ag p24 & p27 » PEG-IFN is only available treatment for CHD, but very low rates of cures Novel therapies in development include Export NTCP » Entry inhibitors to prevent re-infection » Farnesyltransferase inhibitors to inhibit posttranslational modification of HDV viral antigens Opportunity for direct antiviral effect with dual RNAi therapeutic approach HBsAg Assembly L-HDAg Entry S-HDAg RNA Pol I » ALN-HBV – Knockdown of S Ag will inhibit HDV life cycle » ALN-HDV – ADAR 1 Nuclear Import gRNA agRNA Silencing RNA genome, replication anti-genome and viral transcripts 162 RNA Pol II Hepatitis E Virus (HEV) Infection Hepatitis E is WW problem 20M infections/yr » » 3M acute cases, a subset develop into fulminant hepatitis 57K deaths (~2%); disproportionately high lethality in pregnant women (~20%) Oro-fecal transmission makes it prevalent in regions with poor sanitation » Sporadic outbreaks in developed countries increasing Clinical manifestations can be severe Acute infection with high risk of chronicity in immunocompromised patients 66% of HEV-infected organ transplant patients develop chronic HEV infection (CHE); 10% develop cirrhosis http://upload.wikimedia.org/wikipedia/commons/thumb/3/33/Hep atitis_E_virus.jpg/230px-Hepatitis_E_virus.jpg No treatment options exist beyond supportive care Vaccine recently approved in China Ribavirin in clinical testing in organ transplant population HEV is RNA virus, ideally susceptible to RNAi HEV genome is polyadenylated single-strand RNA translated into 6 proteins Kamar et al Emerging Infect. Dis. (2011) 163 Hepatic Infectious Diseases Programs and Target Opportunities HBV HDV HEV Others Pathogen Targets Host Factors RNA viral genomes, replication intermediates, viral transcripts Subverted to support pathogen lifecycle; Non essential to host Immune Modulators Immune evasion PD-L1 164 Liver-Restricted Immune Reactivation ALN-PDL Obligate liver pathogens exploit tolerant liver environment » Enhance immune suppression via multiple mechanisms Activation of PD1/PD-L1 immune checkpoint associated with establishment and maintenance of chronic infections, including HBV RNAi knockdown of liver PD-L1 would enhance NK and T-cell activity against infected hepatocytes » Without risk of broad systemic tolerance suppression Alnylam POC studies conducted in mouse model of adenoviral infection » Demonstrated that PD-L1 knockdown associated with increased viral clearance 165 Hepatic Infectious Disease STAr Summary (1/2) Significant opportunity for RNAi therapeutics as transformative medicines in hepatic infectious diseases Major global health problems with significant disease burden Many hepatocyte-specific pathogens and/or pathogens with major liver disease pathology Reproducible and modular RNAi therapeutic platform as approach for emerging pathogens » Potential for expedited timelines Emerging profile for ESC-GalNAc-siRNA highly attractive » » » » Potent and durable, with very wide therapeutic index Durability supports qM to qQ subcutaneous dose regimens Room temperature stability for global needs Potential to achieve multi-targeting for broad coverage and resistance 166 Hepatic Infectious Disease STAr Summary (2/2) Alnylam Hepatic Infectious Disease STAr advancing key programs Established human POC with RNA therapeutics » Regulus RG-101 in HCV employing Alnylam GalNAc-conjugate platform ALN-HBV DC selected and on track for IND in late ’15 » Best-in-class potential with subcutaneous, qM profile and wide therapeutic index Additional programs in development for HDV infection and chronic liver infections via liver-specific PD-L1 blockade » Multi-pronged strategy for HBV and other hepatic infectious diseases Many additional pipeline programs » Expect 3-4 INDs over next 5-6 years Represents new opportunities for partnership Alnylam to retain meaningful product rights in core markets Leverage partner for expanded effort and geographic scope 167 Barry Greene President and Chief Operating Officer Looking Ahead 168 Alnylam RNAi Therapeutics Strategy A Reproducible and Modular Path for Innovative Medicines 2. POC achieved in Phase 1 Blood-based biomarker with strong disease correlation GCCCCUGGAGGG » e.g., Serum TTR, thrombin generation, hemolytic activity, LDL-C, HBsAg levels 3. Definable path to approval and market 1. Liver-expressed target gene Involved in disease with high unmet need Validated in human genetics GalNAc-siRNA enables SC dosing with wide therapeutic index Established endpoints Focused trial size Large treatment effect Collaborative approach with physicians, regulators, patient groups, and payers 169 Alnylam Strategic Therapeutic Areas (STAr) Genetic Medicines Genetically validated liver targets for rare orphan diseases High unmet needs in focused markets SC dosing Alnylam direct commercial in NA and EU Genzyme alliance for ROW commercial » Through end-2019 Cardio-Metabolic Disease Genetically validated liver targets for dyslipidemia, NASH, type 2 diabetes, and hypertension Development path in morbid subpopulations Access to larger populations thereafter Emerging genetics qM or qQ SC dosing Partnership opportunities Hepatic Infectious Disease Liver pathogen and/or host targets Sub-acute duration of treatment (~12 mo) Multiple siRNAs possible, if needed Defined opportunities with very large markets qM or qQ SC dosing Partnership opportunities 17 0 Alnylam Development Pipeline Discovery Development Phase 1 Phase 2 Phase 3 GENETIC MEDICINES Patisiran (ALN-TTR02) TTR-Mediated Amyloidosis Revusiran (ALN-TTRsc) ALN-AT3 Hemophilia and Rare Bleeding Disorders ALN-CC5 Complement-Mediated Diseases ALN-AS1 Hepatic Porphyrias Alpha-1 Antitrypsin Deficiency ALN-AAT Beta-Thalassemia/Iron-Overload Disorders ALN-TMP Primary Hyperoxaluria Type 1 ALN-GO1 Additional Genetic Medicine Programs CARDIO-METABOLIC DISEASES ALN-PCSsc Hypercholesterolemia Mixed Hyperlipidemia/Hypertriglyceridemia ALN-ANG Hypertriglyceridemia ALN-AC3 Hypertension/Preeclampsia ALN-AGT Additional Cardio-Metabolic Programs HEPATIC INFECTIOUS DISEASES Hepatitis B Virus Infection ALN-HBV Hepatitis D Virus Infection ALN-HDV Chronic Liver Infection ALN-PDL Additional Hepatic Infectious Disease Programs Multi-Year Pipeline Progression D Clinical Data Expected PATISIRAN Phase 2 OLE (ALN-TTR02) TTR-FAP APOLLO Phase 3 REVUSIRAN Phase 2 OLE (ALN-TTRsc) TTR-FAC ENDEAVOUR Phase 3 Phase 1 ALN-AT3 (Hemophilia and RBDs) 2015 2016 D D Subsequent 1-2 Years D D D D D D D D Phase 2 D Phase 3 Phase 1/2 ALN-CC5 (Complement Disease) D D D Phase 2 D Phase 3 ALN-AS1 Phase 1 (Hepatic Porphyrias) Phase 2/3 D D D Phase 1 ALN-AAT (Alpha-1 Antitrypsin Deficiency) D Phase 2 Phase 3 ALN-GO1 Phase 1 (Primary Hyperoxaluria) Phase 2/3 Phase 1 ALN-PCSsc (Hypercholesterolemia) Phase 2 D D D D Phase 3 ALN-HBV Phase 1 (Hepatitis B Virus Infection) Phase 2 Additional Programs Research Additional Phase 1 and 2 Studies D Alnylam 2014-2015 Pipeline Goals 2015 Late ‘14 PATISIRAN APOLLO Phase 3 Accrual (ALN-TTR02) TTR-FAP Phase 2 OLE data ENDEAVOUR Phase 3 Start REVUSIRAN (ALN-TTRsc) TTR-FAC ENDEAVOUR Phase 3 Accrual Phase 2 OLE Data ALN-AT3 Phase 1 Data (Hemophilia and RBDs) Start Phase 2 CTA Filing ALN-CC5 (Complement Disease) Start Phase 1/2 Initial Phase 1/2 Data ALN-AS1 CTA Filing (Hepatic Porphyrias) Start Phase 1 ALN-AAT (Alpha-1 Antitrypsin Deficiency) ALN-GO1 (Primary Hyperoxaluria) IND Filing Development Candidate ALN-PCSsc Start Phase 1 (Hypercholesterolemia) Initial Phase 1 Data ALN-HBV (Hepatitis B Virus Infection) IND Filing * Early is Q1-Q2, Mid is Q2-Q3, and Late is Q3-Q4; **IND or IND equivalent Early Mid Late Ongoing Hepatic Infectious Disease STAr Q&A 174 Thank You www.alnylam.com